Ocular Therapeutix, Inc. (OCUL)
Nasdaq: OCUL · Pharmaceutical Preparations · Bedford, MA · filing with the SEC since 2007
Who owns Ocular Therapeutix, Inc.
As filed with the SECHolders of 5% or more
4
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Nov 5, 2025 says.
Directors and officers
18
report now, of 37 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · COMMON STOCK · 12.3% in Jul 8, 2025
Deep Track Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 5.13% in Feb 10, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock · 5.8% in Oct 17, 2025
Summer Road LLC
SCHEDULE 13G · filed Dec 8, 2025 · Common stock ("Common Shares")
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 7.3% in Nov 14, 2025
Opaleye Management Inc.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What OCUL reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 5, 2026.
Insider tradesForm 4
29sales
1purchases
25sales on a scheduled plan
8people selling
$3.3Msold, in dollars
$500,000bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Dugel Pravin | Executive Chairman, President and CEO | 5 | $1.9M | 5 | 0 | $0 |
| Notman Donald | Chief Operating Officer | 4 | $200,000 | 0 | 0 | $0 |
| Saroj Namrata | Chief Business Officer | 1 | $200,000 | 1 | 0 | $0 |
| Heier Jeffrey S. | Chief Scientific Officer | 5 | $200,000 | 5 | 0 | $0 |
| Kaiser Peter | Chief Development Officer | 5 | $200,000 | 5 | 0 | $0 |
| Nayak Sanjay | Chief Strategy Officer | 5 | $200,000 | 5 | 0 | $0 |
| Waheed Nadia | Chief Medical Officer | 3 | $200,000 | 3 | 0 | $0 |
| Anderman Todd | Chief Legal Officer | 1 | $100,000 | 1 | 0 | $0 |
| Lindstrom Richard L Md | director | 0 | $0 | 0 | 1 | $500,000 |